Wird geladen...
Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
Dipeptidyl-peptidase-IV (DPP-4) inhibitors are oral antidiabetic agents that can be administered as monotherapy in patients with contraindications to metformin or metformin intolerance, and in combination with other oral compounds and/or insulin. DPP-4 inhibitors act in a glucose-dependent manner an...
Gespeichert in:
| Veröffentlicht in: | Ther Clin Risk Manag |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4437596/ https://ncbi.nlm.nih.gov/pubmed/25999728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S67076 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|